Status | Study |
Completed |
Study Name: Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001 EXT1)(COMPLETED) Condition: Pneumococcal Vaccines Date: 2010-10-04 Interventions: Biological: Adults-Adjuvanted V114 |
Completed |
Study Name: Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) Condition: Lymphoma Date: 2008-10-09 Interventions: Drug: vorinostat Parts I & II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per |
Terminated |
Study Name: Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED) Condition: Diabetes Mellitus, Type 2 Date: 2008-10-03 Interventions: Drug: MK-0941 MK-0941 tablets |
Completed |
Study Name: An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) Condition: Proteinuria Date: 2007-12-03 Interventions: Drug: Losartan Potassium |
Completed |
Study Name: Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) Condition: Leukemia, Myelocytic, Acute Myelodysplastic Syndromes Myelodysplastic Syndromes Date: 2007-05-24 Interventions: Drug: vorinostat Other Names: |
Completed |
Study Name: The Health-Related Quality of Life in Patients With Hereditary Multiple Exostoses Condition: Exostoses, Multiple Hereditary Date: 2007-05-15 |
Terminated |
Study Name: Establishing the Genetic Profile of Multiple Hereditary Exostoses (HME) in Families of BC Condition: Exostoses, Multiple Hereditary Date: 2007-05-14 |
Suspended |
Study Name: Gene Mutations and Orthopaedic Symptoms Correlation of Multiple Hereditary Exostoses: Multicentre Project Condition: Exostoses, Multiple Hereditary Date: 2007-05-14 |
Completed |
Study Name: Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1) Condition: Mesothelioma Lung Cancer Date: 2005-08-05 Interventions: Drug: vorinostat Vorinostat th |
Completed |
Study Name: Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) Condition: Date: 2024-03-28 |